SCHEMBL770635

SCHEMBL770635

NCCCNC(=O)N1CCCC2CCCCC21

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
DPP7 Q9UHL4 1/20 0.43
EPHX2 P34913 2/20 0.42
TPSAB1 Q15661 3/20 0.42
TPSD1 Q9BZJ3 3/20 0.42
TPSG1 Q9NRR2 3/20 0.42
POLB P06746 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
NPSR1 Q6W5P4 1/20 0.38
FKBP1A P62942 1/20 0.38
DRD2 P14416 1/20 0.37
DRD4 P21917 1/20 0.37
HSD11B1 P28845 3/20 0.37
HRH3 Q9Y5N1 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL771962 0.85 NPC1 (0.49) NPC1RAB9ASMN1; SMN2EPHX2POLB
SCHEMBL27004594 0.85 DPP7 (0.40) NPC1RAB9ASMN1; SMN2DPP7TPSAB1
SCHEMBL772280 0.84 NPC1 (0.48) NPC1RAB9ASMN1; SMN2EPHX2DRD2
SCHEMBL786891 0.84 NPC1 (0.51) NPC1RAB9ASMN1; SMN2EPHX2POLB
SCHEMBL771740 0.81 NPC1 (0.45) NPC1RAB9ASMN1; SMN2EPHX2POLB
SCHEMBL770194 0.81 EPHX2 (0.49) NPC1RAB9ASMN1; SMN2EPHX2POLB
SCHEMBL769965 0.81 NPC1 (0.50) NPC1RAB9ASMN1; SMN2EPHX2POLB
SCHEMBL770208 0.81 NPC1 (0.54) NPC1RAB9ASMN1; SMN2EPHX2POLB
SCHEMBL770598 0.80 NPC1 (0.44) NPC1RAB9ASMN1; SMN2EPHX2TDP1
SCHEMBL770491 0.80 NPC1 (0.44) NPC1RAB9ASMN1; SMN2EPHX2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 NPC1 97/4885RAB9A 2187/4885SMN1; SMN2 3653/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 NPC1 104/4885RAB9A 2217/4885SMN1; SMN2 3637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.